{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Established Pharmacologic Class [EPC]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT02121145: Phase 4 Interventional Unknown status Healthy
(2013)
Source URL:
First approved in 1992
Source:
BLA103123
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Standardized Cat Pelt Ap by Jubilant Hollisterstier Llc [Canada]
Source URL:
First approved in 1992
Source:
BLA103061
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA103931
(1980)
Source URL:
First approved in 1980
Source:
BLA103931
Source URL:
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
THYROLAR-0.25 by ALLERGAN
(1969)
Source URL:
First approved in 1969
Source:
THYROLAR-0.25 by ALLERGAN
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
HB Triple Play by Wausau Chemical
(2019)
Source URL:
First approved in 2019
Source:
HB Triple Play by Wausau Chemical
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Approved Rx
(1998)
Source:
BLA103770
(1998)
Source URL:
First approved in 1998
Source:
BLA103770
Source URL:
Class:
CONCEPT